AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Veracyte to Present at Upcoming Investor Conferences

May 26, 2021 GMT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 26, 2021--

Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson, chairman, chief executive officer and incoming executive chairman, and Marc Stapley, incoming chief executive officer, are scheduled to participate in two upcoming virtual investor conferences:

  • William Blair Growth Stock Conference
    Fireside Chat on Tuesday, June 1, 2021, at 11:20 a.m. Central Time

  • Jefferies Virtual Healthcare Conference
    Presentation on Friday, June 4, 2021, at 11:30 a.m. Eastern Time

ADVERTISEMENT

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days following the conclusion of each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20210526006025/en/

CONTACT: Investor and Media Contact:

Tracy Morris

Vice President of Corporate Communications

& Investor Relations

650-380-4413

tracy.morris@veracyte.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS RESEARCH PHARMACEUTICAL SCIENCE

SOURCE: Veracyte

Copyright Business Wire 2021.

PUB: 05/26/2021 03:00 PM/DISC: 05/26/2021 03:02 PM

http://www.businesswire.com/news/home/20210526006025/en